Precigen (PGEN) said Tuesday that a biologics license application for PRGN-2012, an investigational gene therapy for the treatment of adults with recurrent respiratory papillomatosis, was accepted by the US Food and Drug Administration for priority review.

The agency set a target action date of Aug. 27 and said that it is not planning to hold an advisory committee meeting to discuss the application.

PRGN-2012 is designed to elicit immune responses directed against cells infected with human papillomavirus 6 or HPV 11, the company said.

The application is supported by data from a clinical study that met its primary safety and efficacy endpoints, Precigen said. The study showed more than 50% of patients achieving complete response and more than 85% of patients experiencing a decrease in surgical interventions in the year after treatment compared to the year prior to treatment.

PGEN shares were over 2% higher in recent trading.

Price: 1.79, Change: +0.03, Percent Change: +2.00